Biotech Values

[drbio45]

visudyne to buy back stock

It is sad that the companies priority is to boost the stock price as opposed to do something meaningful with 100 million dollars

There are many companies with terrific technologies that can't bring them to market because they don't have the cash, and this company is wasting the cash on supporting the stock.

If they inlicensed a good drug and paid for the trial the stock would go up because of a value driver

Very sad